Show simple item record

dc.contributor.authorGhidini, Men_US
dc.contributor.authorHahne, JCen_US
dc.contributor.authorFrizziero, Men_US
dc.contributor.authorTomasello, Gen_US
dc.contributor.authorTrevisani, Fen_US
dc.contributor.authorLampis, Aen_US
dc.contributor.authorPassalacqua, Ren_US
dc.contributor.authorValeri, Nen_US
dc.coverage.spatialFranceen_US
dc.date.accessioned2018-11-27T15:19:13Z
dc.date.issued2018-08en_US
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/30006826en_US
dc.identifier10.1007/s11523-018-0580-3en_US
dc.identifier.citationTarget Oncol, 2018, 13 (4), pp. 423 - 436en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2957
dc.identifier.eissn1776-260Xen_US
dc.identifier.doi10.1007/s11523-018-0580-3en_US
dc.description.abstractReceptor tyrosine kinases (RTKs) are widely expressed transmembrane proteins that act as receptors for growth factors and other extracellular signalling molecules. Upon ligand binding, RTKs activate intracellular signalling cascades, and as such are involved in a broad variety of cellular functions including differentiation, proliferation, migration, invasion, angiogenesis, and survival under physiological as well as pathological conditions. Aberrant RTK activation can lead to benign proliferative conditions as well as to various forms of cancer. Indeed, more than 70% of the known oncogene and proto-oncogene transcripts involved in cancer code for RTKs. Consequently, these receptors are broadly studied as targets in the treatment of different tumours, and a large variety of small-molecule tyrosine kinase inhibitors (TKIs) are approved for therapy. In most cases, patients develop resistance to the TKIs within a short time. MicroRNAs are short (18-22 nucleotides) non-protein-coding RNAs that fine-tune cell homeostasis by controlling gene expression at the post-transcriptional level. Deregulation of microRNAs is common in many cancers, and increasing evidence exists for an important role of microRNAs in the development of resistance to therapies, including TKIs. In this review we focus on the role of microRNAs in mediating resistance to small-molecule TKIs in solid tumours.en_US
dc.format.extent423 - 436en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://www.rioxx.net/licenses/under-embargo-all-rights-reserveden_US
dc.titleMicroRNAs as Mediators of Resistance Mechanisms to Small-Molecule Tyrosine Kinase Inhibitors in Solid Tumours.en_US
dc.typeJournal Article
dcterms.dateAccepted2018-08-01en_US
rioxxterms.versionofrecord10.1007/s11523-018-0580-3en_US
rioxxterms.licenseref.startdate2018-08en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfTarget Oncolen_US
pubs.issue4en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Gastrointestinal Cancer Biology and Genomics
pubs.publication-statusPublisheden_US
pubs.volume13en_US
pubs.embargo.termsNot knownen_US
icr.researchteamGastrointestinal Cancer Biology and Genomicsen_US
dc.contributor.icrauthorValeri, Nicolaen_US
dc.contributor.icrauthorHahne, Jensen_US
dc.contributor.icrauthorLampis, Andreaen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record